AMARIN CORP PLC\UK (AMRN) Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - General
Amarin Corporation plc NASDAQ:AMRN Healthcare · Biotechnology
Mkt Cap $509.13M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 3
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
Amarin reported Q3 2026 revenue of $39.6 million, down 20% year-over-year, driven by a 30% decline in U.S. VASCEPA sales amid generic competition and lower net pricing.
The company posted its first profitable quarter in over two years with net income of $0.2 million, as operating expenses fell 44% following its $70 million cost-savings program. Cash and short-term investments rose to $323.4 million with no debt.
Europe in-market demand for VAZKEPA grew an estimated 68% YoY under the Recordati partnership, and Amarin held 47% U.S. IPE market share. Management is working with Barclays as exclusive financial advisor on a strategic value-maximization effort, and cited EMT2 trial data suggesting potential new colorectal-cancer-liver-metastasis applications for IPE.
• 4d ago AI analysis › Press Release ⚠ 2
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Amarin's VAZKEPA/VASCEPA failed the primary endpoint of progression-free survival in the Phase 3 EMT2 liver metastasis trial (median PFS 13.5 vs 12.9 months, HR 0.89, p=0.329).
However, the key secondary endpoint of overall survival was statistically significantly improved: 5-year OS of 62.0% versus 45.1% with placebo, an approximately 32% reduction in the risk of death (HR 0.68, p=0.030).
Management is encouraged by the survival signal and sees potential to explore IPE beyond cardiovascular disease, noting European patent protection through 2039; further analyses and study are required before any oncology opportunity can be validated.
• 7d ago AI analysis › Press Release
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
Amarin Corporation will report third quarter 2026 financial results on Wednesday, October 28, 2026, with a press release issued pre-market.
A conference call with senior management follows at 8:00 a.m. ET, with webcast access via the company's investor relations site.
No results or guidance were disclosed in this scheduling notice.
• 11d ago AI analysis › Press Release
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Amarin highlighted new mechanistic and post-hoc data from the REDUCE-IT trial at the ESC Congress 2026, expanding understanding of treatment adherence, lipoprotein(a) biology, and coagulation pathways.
The 2026 ESC/European Renal Association guidelines recognized evidence from REDUCE-IT, adding to the 70+ medical societies globally that support the use of icosapent ethyl for cardiovascular risk reduction.
Mechanistic studies presented indicated that EPA limits rapid oxidation of Lp(a) and reduces tissue factor expression, providing further biological support for the clinical benefits of VASCEPA and VAZKEPA.
• 2mo ago AI analysis › Press Release
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
Amarin presented new post hoc data from the REDUCE-IT trial showing that highly adherent patients on icosapent ethyl (IPE) experienced approximately 30% relative risk reduction in major cardiovascular events.
In patients who discontinued treatment after a mean of 2.3 years, benefits persisted with a hazard ratio of 0.73 over the next one to four years, suggesting a 'legacy' effect.
These findings were presented at the ESC Congress 2026 and reinforce the importance of long-term adherence to treatment for high-risk cardiovascular patients.
• 2mo ago AI analysis › Press Release
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
Amarin announced that new analyses from the REDUCE-IT trial and mechanistic data on icosapent ethyl will be presented at the European Society of Cardiology Congress 2026 in Munich.
The presentations, led by international academic collaborators, will cover topics such as treatment adherence, long-term outcomes, and the effects on lipoprotein(a) and coagulation biomarkers.
These analyses add to the body of evidence supporting VASCEPA and VAZKEPA, which have been prescribed more than 31 million times in the U.S.
• 2mo ago AI analysis › Press Release ⚠ 1
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Amarin reported Q2 2026 net revenue of $42.2 million, a 42% decrease from the prior year, primarily due to the absence of a $25 million upfront payment received from Recordati in 2025. Despite the revenue decline, the company narrowed its net loss to $7.7 million and generated positive cash flow for the third consecutive quarter.
Operating expenses fell 59% year-over-year to $27.0 million, driven by the completed $70 million cost savings initiative associated with the shift to a fully partnered international model. Cash position grew to $314.6 million, and the company remains debt-free.
In-market demand for VASCEPA/VAZKEPA increased 59% globally and 69% in Europe, while the U.S. IPE market share rose to 48%. Amarin expects cash to grow approximately 10% by year-end 2026.
• 3mo ago AI analysis › Press Release
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
Amarin Corporation announced that it will report its second quarter 2026 financial results on Wednesday, July 29, 2026.
The press release will be issued before the market opens, followed by a conference call with senior management at 8:00 a.m. ET.
Access details for the live call and replay are available via telephone and webcast on the company's investor relations website.
• 3mo ago AI analysis › Press Release ⚠ 2
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Amarin responded to the FDA approval of injectable APOC3 therapies for severe hypertriglyceridemia, asserting that VASCEPA remains a critical first-line option due to its established efficacy and lower cost.
The company highlighted a significant cost differential, noting VASCEPA's annual wholesale acquisition cost is approximately $4,200 per patient compared to $40,000 for the new injectables.
Management cited over 30 million global prescriptions and reaffirmed guideline support for VASCEPA's ability to reduce cardiovascular risk by 25% when added to statin therapy.
• 4mo ago AI analysis › Press Release
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
Amarin presented new post-hoc data from the REDUCE-IT trial at the European Atherosclerosis Society Congress, showing that risk-weighted apoB (RW-apoB) better identifies residual cardiovascular risk in statin-treated patients than traditional biomarkers.
The analysis of 3,485 placebo-arm participants found RW-apoB levels were approximately 30% higher than measured apoB, suggesting underrecognition of lipid-associated risk. RW-apoB demonstrated superior risk prediction compared to LDL-C, non-HDL-C, and standard apoB.
The company highlighted that these findings support the clinical role of its lead asset, icosapent ethyl (VASCEPA/VAZKEPA), which has been prescribed over 25 million times and is included in recent ESC/EAS and ACC/AHA guidelines.
• 5mo ago AI analysis › Press Release
Amarin Reports 2026 First Quarter Financial Results
Amarin reported Q1 2026 revenue of $45.1 million, up 7% year-over-year, driven by higher international sales and licensing revenue despite flat U.S. product sales.
Operating expenses dropped 31% to $29.1 million due to the global restructuring, narrowing the net loss to $10.5 million from $15.7 million in the prior year.
The company generated positive cash flow for the second consecutive quarter and reiterated its expectation for full-year 2026 positive cash flow.
• 6mo ago AI analysis › 
